Cellectis Announces Conference Call To Discuss Recent Recombinant DNA Advisory Committee (RAC) Meeting
Published on December 16, 2016
December 16, 2016 – New York (N.Y.) – Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that it will hold a conference call to discuss the National Institutes of Health Recombinant DNA Advisory Committee (RAC) meeting held on December 14, 2016.
The call will be held this Tuesday, December 20, 2016 at 8:30 am Eastern Time and can be accessed with the following dial-in information
Dial-in information:
Participant dial in (Toll Free US & Canada): 877-407-3104
Participant international dial in: +1 201-493-6792
This conference call will be recorded and made available for replay for 14 days as follows:
Conference ID #: 13625168
Replay Dial-In (Toll Free US & Canada): 877-660-6853
Replay Dial-In (International): 201-612-7415
Expiration Date: 1/3/17